Q2-osavuosiraportti
Vain PDF
82 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
1 000
Myynti
Määrä
2 657
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 143 | - | - | ||
| 1 200 | - | - | ||
| 9 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Ylin
7,165VWAP
Alin
6,755VaihtoMäärä
3,8 552 965
VWAP
Ylin
7,165Alin
6,755VaihtoMäärä
3,8 552 965
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 553 965 | 553 965 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 553 965 | 553 965 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| 2024 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Q4-osavuosiraportti | 25.2. | |
| 2024 Q3-osavuosiraportti | 21.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11.11.11.11.And here we go, another set of warrants exercised. I said it once, and I‘ll say it again. The company needs FUNDING and it will result in a DOWNWARD trend for the foreseeable future. But of course the hyperoptimists say this wont fall at all. People do the most extraordinary mental gymnastics to prove that their false views are definitely correct.2 päivää sitten2 päivää sittenThey have nothing relevant to bring to a conversation. All they do is build hype in their echo chamber/bubble. It‘s weird and I highly recommend anyone who is serious about their money to avoid people who refuse to accept or even discuss the realities of an investment. It‘s the same energy you can find on WallStreetBets on reddit. The discord is great for keeping up with a news feed and to have insight into stuff like Cereno’s patent portfolio, but the general text channels are just full to the brim of people who will never seriously discuss an opinion unless it‘s „this is going to the moon quaranteed“ I‘m invested in this, fairly heavily so. I‘m optimistic about the prospect of an exit deal. Yet I’m still not going to repeat the same news over and over like that somehow magically erases the problems the company is facing. Neither am I going to act like the topline data from P2 for CS01 or P1 for CS014 is a quarantee that the drugs will make it to market when they contained minimal efficacy data and endpoints. Nor am I going to say something stupid like „a partnership is just around the corner“ when the reality is no one actually knows, except for Cereno themselves and perhaps their advisors if a deal is being discussed. It‘s a waste of time to converse with someone, whose only comments are „we‘ll see who was right in the end“ and „you are only saying stuff to talk down the price“ 😅
·10.11.Phase 2b and at the same time already patients using their medicine. The company is valued at 200 mill us so there is room to rise, with positive results. If a bid is to be made for the company, it must be at least x10, anything below that is a no from here. Happy working from the patient ones.Poistettu·10.11.Poistettu·10.11.10x or more sounds very reasonable at exit. The data is there.✔️ Now we'll see what happens. This is not a buy or sell recommendation…
·10.11.4️⃣ 🌍 Global Collaboration and Vision The upcoming Phase IIb will be conducted in partnership with a leading global CRO, with plans for parallel regulatory submissions in other regions. As noted by Rahul Dr. Agrawal (CMO) and Sten R. Sörensen (CEO), this milestone reflects not only Cereno’s scientific rigor but also its commitment to transforming patient care and creating shareholder value. What are they saying here 🤔 that they have a partner to proceed with Phase IIb?10.11.10.11.A CRO partner, yes. A CRO partner is a Contract Research Organization, meaning the company pays them to facilitate the global research. It‘s common for small biotechs, as the companies themselves rarely have the network, outreach or plain out resources to handle all of these aspects themselves. You can think of it in the sense that a small cap biotech like Cereno owns the patents and conducts preliminary research on their drugs. Once they identify a potential compound and clinical markers for it‘s use they use a CRO to accelerate the trial process as they get global access, help with designing and issuing the clinical trial etc etc. It‘s NOT the partnership people are waiting for, which is a monetary partnership from a Big Pharma company to fund the trials / plain out buy Cereno‘s portfolio/shares.·10.11.Thanks for a good answer 👍🏻 Then it wasn't as exciting as I first thought!
·29.10. · MuokattuIs Cereno pumped? Is Cereno in a tailspin? (my thoughts) Bad economy. Loan-financed business. Loans that will soon be repaid. Is an exit/deal within the realm of possibilities? Time is short, I suppose, given the financial situation.
·31.10.That's how it always is, roughly like a coin that has three sides.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
82 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.11.11.11.And here we go, another set of warrants exercised. I said it once, and I‘ll say it again. The company needs FUNDING and it will result in a DOWNWARD trend for the foreseeable future. But of course the hyperoptimists say this wont fall at all. People do the most extraordinary mental gymnastics to prove that their false views are definitely correct.2 päivää sitten2 päivää sittenThey have nothing relevant to bring to a conversation. All they do is build hype in their echo chamber/bubble. It‘s weird and I highly recommend anyone who is serious about their money to avoid people who refuse to accept or even discuss the realities of an investment. It‘s the same energy you can find on WallStreetBets on reddit. The discord is great for keeping up with a news feed and to have insight into stuff like Cereno’s patent portfolio, but the general text channels are just full to the brim of people who will never seriously discuss an opinion unless it‘s „this is going to the moon quaranteed“ I‘m invested in this, fairly heavily so. I‘m optimistic about the prospect of an exit deal. Yet I’m still not going to repeat the same news over and over like that somehow magically erases the problems the company is facing. Neither am I going to act like the topline data from P2 for CS01 or P1 for CS014 is a quarantee that the drugs will make it to market when they contained minimal efficacy data and endpoints. Nor am I going to say something stupid like „a partnership is just around the corner“ when the reality is no one actually knows, except for Cereno themselves and perhaps their advisors if a deal is being discussed. It‘s a waste of time to converse with someone, whose only comments are „we‘ll see who was right in the end“ and „you are only saying stuff to talk down the price“ 😅
- ·10.11.Phase 2b and at the same time already patients using their medicine. The company is valued at 200 mill us so there is room to rise, with positive results. If a bid is to be made for the company, it must be at least x10, anything below that is a no from here. Happy working from the patient ones.Poistettu·10.11.Poistettu·10.11.10x or more sounds very reasonable at exit. The data is there.✔️ Now we'll see what happens. This is not a buy or sell recommendation…
- ·10.11.4️⃣ 🌍 Global Collaboration and Vision The upcoming Phase IIb will be conducted in partnership with a leading global CRO, with plans for parallel regulatory submissions in other regions. As noted by Rahul Dr. Agrawal (CMO) and Sten R. Sörensen (CEO), this milestone reflects not only Cereno’s scientific rigor but also its commitment to transforming patient care and creating shareholder value. What are they saying here 🤔 that they have a partner to proceed with Phase IIb?10.11.10.11.A CRO partner, yes. A CRO partner is a Contract Research Organization, meaning the company pays them to facilitate the global research. It‘s common for small biotechs, as the companies themselves rarely have the network, outreach or plain out resources to handle all of these aspects themselves. You can think of it in the sense that a small cap biotech like Cereno owns the patents and conducts preliminary research on their drugs. Once they identify a potential compound and clinical markers for it‘s use they use a CRO to accelerate the trial process as they get global access, help with designing and issuing the clinical trial etc etc. It‘s NOT the partnership people are waiting for, which is a monetary partnership from a Big Pharma company to fund the trials / plain out buy Cereno‘s portfolio/shares.·10.11.Thanks for a good answer 👍🏻 Then it wasn't as exciting as I first thought!
- ·29.10. · MuokattuIs Cereno pumped? Is Cereno in a tailspin? (my thoughts) Bad economy. Loan-financed business. Loans that will soon be repaid. Is an exit/deal within the realm of possibilities? Time is short, I suppose, given the financial situation.·31.10.That's how it always is, roughly like a coin that has three sides.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 000
Myynti
Määrä
2 657
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 143 | - | - | ||
| 1 200 | - | - | ||
| 9 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Ylin
7,165VWAP
Alin
6,755VaihtoMäärä
3,8 552 965
VWAP
Ylin
7,165Alin
6,755VaihtoMäärä
3,8 552 965
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 553 965 | 553 965 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 553 965 | 553 965 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| 2024 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Q4-osavuosiraportti | 25.2. | |
| 2024 Q3-osavuosiraportti | 21.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
82 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 27.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 27.8. | |
| 2024 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 22.5. | |
| 2024 Q4-osavuosiraportti | 25.2. | |
| 2024 Q3-osavuosiraportti | 21.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.11.11.11.And here we go, another set of warrants exercised. I said it once, and I‘ll say it again. The company needs FUNDING and it will result in a DOWNWARD trend for the foreseeable future. But of course the hyperoptimists say this wont fall at all. People do the most extraordinary mental gymnastics to prove that their false views are definitely correct.2 päivää sitten2 päivää sittenThey have nothing relevant to bring to a conversation. All they do is build hype in their echo chamber/bubble. It‘s weird and I highly recommend anyone who is serious about their money to avoid people who refuse to accept or even discuss the realities of an investment. It‘s the same energy you can find on WallStreetBets on reddit. The discord is great for keeping up with a news feed and to have insight into stuff like Cereno’s patent portfolio, but the general text channels are just full to the brim of people who will never seriously discuss an opinion unless it‘s „this is going to the moon quaranteed“ I‘m invested in this, fairly heavily so. I‘m optimistic about the prospect of an exit deal. Yet I’m still not going to repeat the same news over and over like that somehow magically erases the problems the company is facing. Neither am I going to act like the topline data from P2 for CS01 or P1 for CS014 is a quarantee that the drugs will make it to market when they contained minimal efficacy data and endpoints. Nor am I going to say something stupid like „a partnership is just around the corner“ when the reality is no one actually knows, except for Cereno themselves and perhaps their advisors if a deal is being discussed. It‘s a waste of time to converse with someone, whose only comments are „we‘ll see who was right in the end“ and „you are only saying stuff to talk down the price“ 😅
- ·10.11.Phase 2b and at the same time already patients using their medicine. The company is valued at 200 mill us so there is room to rise, with positive results. If a bid is to be made for the company, it must be at least x10, anything below that is a no from here. Happy working from the patient ones.Poistettu·10.11.Poistettu·10.11.10x or more sounds very reasonable at exit. The data is there.✔️ Now we'll see what happens. This is not a buy or sell recommendation…
- ·10.11.4️⃣ 🌍 Global Collaboration and Vision The upcoming Phase IIb will be conducted in partnership with a leading global CRO, with plans for parallel regulatory submissions in other regions. As noted by Rahul Dr. Agrawal (CMO) and Sten R. Sörensen (CEO), this milestone reflects not only Cereno’s scientific rigor but also its commitment to transforming patient care and creating shareholder value. What are they saying here 🤔 that they have a partner to proceed with Phase IIb?10.11.10.11.A CRO partner, yes. A CRO partner is a Contract Research Organization, meaning the company pays them to facilitate the global research. It‘s common for small biotechs, as the companies themselves rarely have the network, outreach or plain out resources to handle all of these aspects themselves. You can think of it in the sense that a small cap biotech like Cereno owns the patents and conducts preliminary research on their drugs. Once they identify a potential compound and clinical markers for it‘s use they use a CRO to accelerate the trial process as they get global access, help with designing and issuing the clinical trial etc etc. It‘s NOT the partnership people are waiting for, which is a monetary partnership from a Big Pharma company to fund the trials / plain out buy Cereno‘s portfolio/shares.·10.11.Thanks for a good answer 👍🏻 Then it wasn't as exciting as I first thought!
- ·29.10. · MuokattuIs Cereno pumped? Is Cereno in a tailspin? (my thoughts) Bad economy. Loan-financed business. Loans that will soon be repaid. Is an exit/deal within the realm of possibilities? Time is short, I suppose, given the financial situation.·31.10.That's how it always is, roughly like a coin that has three sides.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 000
Myynti
Määrä
2 657
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 143 | - | - | ||
| 1 200 | - | - | ||
| 9 | - | - | ||
| 100 | - | - | ||
| 100 | - | - |
Ylin
7,165VWAP
Alin
6,755VaihtoMäärä
3,8 552 965
VWAP
Ylin
7,165Alin
6,755VaihtoMäärä
3,8 552 965
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 553 965 | 553 965 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 553 965 | 553 965 | 0 | 0 |